Table III.

Dose-dependent effect of LPS on survival and peak plasma TNF levels of d-galactosamine-sensitized mice treated with saline or anti-LBP mAbsa

LPS (ng/mouse)LBP Activityb (FU)TNF (pg/ml)cDeaths/Total
Saline5015.7 ± 2.42315 ± 5607 /9 (78%)
125017.0 ± 4.54850 ± 32509 /9 (100%)
2A503.9 ± 0.05d155 ± 75d1 /9 (11%)e
250ND2275 ± 14506 /6 (100%)
12504.0 ± 0.07d4740 ± 25609 /9 (100%)
  • a Mice received an i.v. injection of 100 μg of clone 2A or saline 15 min before the indicated doses of LPS were administered i.v. Data are the mean ± SD of two experiments.

  • b LBP activity was assessed by the capacity of the plasma collected 7 h after LPS challenge to enhance FITC-LPS to CHO/muCD14+ cells. In the absence of plasma, the negative control without LBP was 4.1 fluorescence units (FU).

  • c Plasma TNF levels were measured 75 min after LPS challenge.

  • d p < 0.05 when compared with the other groups by ANOVA.

  • e p < 0.02 by Fisher’s exact test comparing mice receiving saline with mice receiving mAbs. According to an ANOVA comparing treatment groups: 1) p = 8 × 10−9, 2) p = 6 × 10−9.